ストックスクリーナーアプリを入手
43.70
7.61%
3.09
プレマーケット:
44.79
1.09
+2.49%
Kymera Therapeutics Inc (KYMR) 最新ニュース
Stephens Reaffirms Overweight Rating for Kymera Therapeutics (NASDAQ:KYMR) - MarketBeat
Kymera announces expansion of KT-474 HS and AD phase 2 studies - MSN
Kymera Therapeutics soars as Sanofi expands phase 2 trials - MSN
Kymera Therapeutics (NASDAQ:KYMR) Trading Down 6.3%Time to Sell? - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Provides Business Update and Preliminary Cash Balance for 2024 - Defense World
Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last? - MSN
How the (KYMR) price action is used to our Advantage - Stock Traders Daily
JPMorgan Chase & Co. Acquires 95,547 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera Provides Pipeline Objectives for 2025, Stock Gains - MSN
Kymera rises after presentation at the J.P. Morgan event - MSN
Kymera Therapeutics Surges 10% on Bold 2025 Roadmap to Revolutio - GuruFocus.com
Kymera stock surges on product pipeline update By Investing.com - Investing.com Canada
Kymera Therapeutics Surges 10% on Bold 2025 Roadmap to Revolutionize Immunology Treatments - Yahoo Finance
Kymera Therapeutics (NASDAQ:KYMR) Trading 6.4% HigherHere's Why - MarketBeat
Kymera reports progress in immunology drug trials By Investing.com - Investing.com South Africa
Kymera Therapeutics Shares Surge Amid 2025 Strategy Unveil - TipRanks
Kymera reports progress in immunology drug trials - Investing.com India
Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs - The Manila Times
Kymera Unveils Ambitious 2025 Immunology Pipeline Plans with $850M Cash Runway - StockTitan
Analysts Set Expectations for KYMR FY2029 Earnings - Defense World
Stifel sustains Buy on Kymera stock amid TPD drug optimism By Investing.com - Investing.com UK
Equities Analysts Set Expectations for KYMR FY2029 Earnings - MarketBeat
Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14 - The Manila Times
Kymera Therapeutics to Present Strategic Roadmap at J.P. Morgan Healthcare Conference - StockTitan
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Insider Sells $130,635.75 in Stock - MarketBeat
(KYMR) Trading Report - Stock Traders Daily
STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space - BioWorld Online
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $53.88 Consensus Price Target from Brokerages - Defense World
Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $53.88 - MarketBeat
Vir Biotechnology (NASDAQ:VIR) & Kymera Therapeutics (NASDAQ:KYMR) Financial Contrast - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Receives “Outperform” Rating from Leerink Partners - Defense World
Leerink sees positive readthrough for Kymera Therapeutics from J&J-Kaken deal - Yahoo Finance
Leerink Partners Reaffirms Outperform Rating for Kymera Therapeutics (NASDAQ:KYMR) - MarketBeat
Trading (KYMR) With Integrated Risk Controls - Stock Traders Daily
Geode Capital Management LLC Sells 996 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
HighTower Advisors LLC Takes $494,000 Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
BMO Capital Initiates Coverage of Kymera Therapeutics (KYMR) with Market Perform Recommendation - MSN
BTIG Initiates Coverage of Kymera Therapeutics (KYMR) with Buy Recommendation - MSN
State Street Corp Has $81.79 Million Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Verition Fund Management LLC - Defense World
(KYMR) Investment Analysis - Stock Traders Daily
Kymera Therapeutics (NASDAQ:KYMR) Now Covered by BTIG Research - MarketBeat
Two Sigma Advisers LP Lowers Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Wellington Management Group LLP Has $218.59 Million Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Research Coverage Started at BMO Capital Markets - Defense World
Kymera: Protein Degradation Could Drive Dupixent-Like Value (NASDAQ:KYMR) - Seeking Alpha
BMO Capital Markets Initiates Coverage on Kymera Therapeutics (NASDAQ:KYMR) - MarketBeat
Thrivent Financial for Lutherans Takes $313,000 Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
The Manufacturers Life Insurance Company Has $6.07 Million Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
BMO sets Kymera Therapeutics target at $55, rates Market Perform By Investing.com - Investing.com Canada
Kymera Therapeutics, Inc. (NASDAQ:KYMR) is Redmile Group LLC's 5th Largest Position - MarketBeat
(KYMR) Long Term Investment Analysis - Stock Traders Daily
4.81%
大文字化:
|
ボリューム (24 時間):